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ABSTRACT 
Background: Hyperlipidemia is a major risk factor for ischemic heart dis- 
ease. Hydroxymethylglutaryl coenzyme A reductase inhibitors ("statins") (eg, 
simvastatin) are considered first-line cholesterol-lowering therapy because they 
are effective and well tolerated, even at high doses. Based on a literature search, 
no studies have been published concerning the effects of simvastatin 20 mg/d in 
Japanese patients who had not previously received lipid-lowering treatment. 
Objective: The aim of this study was to assess the clinical tolerability and 
effectiveness of simvastatin 20 mg/d in achieving the target lipid concentrations 
recommended in the 2002 Japan Atherosclerosis Society (JAS) guidelines in 
Japanese patients with hyperlipidemia. 
Methods: This prospective, open-label pilot study was conducted at 
Kashiwa Hospital, Jikei University School of Medicine, Kashiwa, Japan. Male 
and postmenopausal female patients aged ___18 to 70 years with hyperlipidemia 
(total cholesterol [TC], ___220 mg/dL; triglycerides [TG], 150-400 mg/dL) who 
had not received lipid-lowering medications for at least 6 months before the 
study were enrolled. Patients received simvastatin 20 mg PO QD for 4 weeks. 
Effectiveness was assessed using serum concentrations of TC, low-density lipo- 
protein cholesterol (LDL-C), TG, and lipid peroxide, measured at 0 (baseline) 
and 4 weeks. Target serum TC and LDL-C concentrations as outlined by the JAS 
were as follows: category A, TC <240 mg/dL and LDL-C <160 mg/dL; category B1 
and B2, TC <220 mg/dL and LDL-C <140 mg/dL; and category C, TC <200 mg/dL 
and LDL-C <120 mg/dL. A subanalysis of the correlation between baseline high- 
density lipoprotein cholesterol (HDL-C) and target achievement rates was con- 
ducted by baseline HDL-C concentration (<50 or ---50 mg/dL). Tolerability was 
assessed using spontaneous reporting of adverse events and laboratory analy- 
sis, including liver function tests. 
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Results: Twenty-two patients participated in the study (16 women, 6 men; 
mean [SD] age, 56.0 [8.0] years; mean [SD] body mass index, 23.6 [3.4] kg/m2). 
Mean serum TC, LDL-C, TG, and lipid peroxide concentrations significantly de- 
creased from baseline (changes,-28.6%,-40.4%,-24.0%, and -14.5%, respec- 
tively; P < 0.001, <0.001, <0.001, and <0.01, respectively). The mean HDL-C 
concentration significantly increased from baseline (change, 7.2%; P < 0.001); 
the mean increase was significantly greater in patients with baseline HDL-C 
<50 mg/dL compared with those with baseline HDL-C ---50 mg/dL (changes, 11.3% vs 
4.4%; P < 0.05). Target TC and LDL-C concentrations were achieved in 90.9% of 
patients. No serious adverse vents were observed, and liver enzyme and crea- 
tine kinase concentrations did not increase to above-normal values. 
Conclusions: The results of this study suggest hat simvastatin 20 mg/d 
might be useful in the clinical treatment ofhyperlipidemia in Japanese patients. 
The study drug was well tolerated. (Curt Ther Res Clin Exp. 2005;66:613-629) 
Copyright © 2005 Excerpta Medica, Inc. 
Key words: simvastatin 20 mg, low high-density lipoprotein cholesterol, 2002 
Japanese Atherosclerosis Society guideline, lipid goal, Japanese hyperlipidemic 
patients. 
INTRODUCTION 
Hyperlipidemia s a major risk factor for coronary heart disease (CHD). 1-3 Evi- 
dence suggests that reducing the serum concentration of low-density lipopro- 
tein cholesterol (LDL-C) decreases the risk for CHD. 4,5 Many large-scale clinical 
studies have found that hydroxymethylglutaryl coenzyme A reductase inhibitors 
("statins") are effective in improving serum cholesterol levels (total cholesterol 
[TC] and LDL-C) and preventing CHD. 3-13 
The advent of statins -20 years ago has made cholesterol lowering relative- 
ly easy. Statins are the first line in cholesterol-lowering therapy because they 
are effective and well tolerated, even at high doses. 3,14-17 However, the doses of 
statins administered to Japanese patients with hyperlipidemia have typically 
been lower compared with those administered to hyperlipidemic patients in 
Western countries, making it difficult o achieve the TC and LDL-C goals (cate- 
gory A, TC <240 mg/dL and LDL-C <160 mg/dL; category B1 and B2, TC <220 mg/dL 
and LDL-C <140 mg/dL; and category C, TC <200 mg/dL and LDL-C <120 mg/dL) 
established in the 2002 Japan Atherosclerosis Society (JAS) guidelines for the 
diagnosis and treatment of atherosclerotic cardiovascular disease. 18,19 
In the 2002 JAS guidelines, hyperlipidemic patients without CHD or CHD risk fac- 
tors other than an elevated LDL-C concentration are classified as category A. 
Patients with CHD risk factors but without CHD are classified as category B, 18,19 
which is divided into 4 subcategories based on the severity of the following CHD 
risk factors other than elevated LDL-C: age (men, ___45 years; women, ---55 years), 
hypertension, diabetes mellitus, smoking habit, family history of CHD, history of 
cerebral infarction, and arteriosclerosis obliterans. Patients in category B1 or B2 
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have 1 and 2 risk factors, respectively, in addition to elevated LDL-C. Patients 
who have diabetes and a history of cerebral infarction, even with no other 
risk factors, are classified as category B3 and B4, respectively. Patients with 
CHD are classified as category C. Target serum TC and LDL-C become increas- 
ingly stringent progressing from category A to C. Because of a high CHD risk, 
more aggressive therapeutic intervention has been recommended for pa- 
tients with diabetes, hypertension, multiple coronary risk factors, and/or 
the metabolic syndrome. 2-5,18 More potent statins have been developed to 
aid high-risk patients in achieving the stringent cholesterol goals in the lat- 
est treatment guideline. After -10 years of low-dose (5 mg/d) simvastatin use 
in clinical practice in Japan, the study of a higher dose (20 mg/d) in Japanese 
patients is timely. A search of the literature using MEDLINE (key terms: sim- 
vastatin, high dose, 20 mg, and Japanese patients; years: 1995-2005) found no 
such studies. 
The aim of this study was to assess the clinical tolerability and effectiveness 
of simvastatin 20 mg/d in achieving the target lipid levels recommended in the 
JAS guidelines in Japanese patients with hyperlipidemia. 
PATIENTS AND METHODS 
Inclusion and Exclusion Criteria 
In this prospective, open-label pilot study, male and postmenopausal fe-
male patients who met the following criteria were consecutively enrolled from 
outpatient clinics at Kashiwa Hospital, Jikei University School of Medicine, 
Kashiwa, Japan: age ___18 to 70 years, fasting serum concentration of TC 
___220 mg/dL, and fasting triglyceride (TG) concentration 150 to 400 mg/dL. 
Patients were excluded from the study if they were severely obese (body 
mass index [BMI], >30 kg/m2), or had clinically evident CHD, endocrine dis- 
ease, or renal or hepatic dysfunction. Patients with diabetes mellitus were 
excluded because, although they commonly have high TG and low high- 
density lipoprotein cholesterol (HDL-C) levels, they rarely have high LDL-C 
levels. Furthermore, drugs to control glycemia often affect lipid metabolism, 
and patients with poorly controlled iabetes commonly have dyslipidemia. 
Patients receiving lipid-lowering drugs within the 6 months before the begin- 
ning of the study were also excluded. 
During the 6 months before the study, patients were advised to modify life- 
style habits (Step-1 diet 4,5 [energy, (25-30) × 22 × height (m) 2 kcal; fat, 20%-25%; 
fiber, >25 g] and exercise 20 minutes 3 times a week). Elevated serum TC 
was confirmed on several occasions during that time. Patients were asked 
not to change their dietary and exercise habits for the duration of the study 
(4 weeks). 
All patients provided written informed consent before participation i  the 
study. The study protocol was approved by the ethics committee at Jikei 
University. Patients were not compensated for participation. 
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Study Design 
Patients were administered one 20-mg tablet of simvastatin QD in the evening 
(after a meal) for 4 weeks. After an overnight fast at baseline (week 0) and study 
end (week 4), each patient's height, weight, and blood pressure were recorded, 
and blood samples were drawn for laboratory analysis. 
Efficacy Assessments 
Serum concentrations of TC; TG; HDL-C; and apolipoprotein (apo) A-l, B, and 
E were measured using conventional methods. 2°LDL-C concentration was esti- 
mated using the Friedewald formula. 21 Non-HDL-C (calculated as the difference 
between the TC and HDL-C concentrations), non-HDL-C/HDL-C ratio, and apo B/ 
apo A-1 ratio were also determined. Lipid peroxide concentrations were mea- 
sured using a fluorometric thiobarbituric acid reactive substance assay (TestWako 
LPO kit, Wako Pure Chemical Industries Co., Osaka, Japan). 22 
The percentages of patients achieving TC and LDL-C targets based on the 
2002 JAS guidelines 18 was assessed by JAS category. 
For subanalysis of the correlation between baseline HDL-C and target achieve- 
ment rates in patients were divided into 2 groups based on baseline HDL-C level 
(<50 [lower] or ---50 mg/dL [higher]), and changes in serum lipid concentra- 
tions, non-HDL-C concentration; on-HDL-C/HDL-C ratio (atherogenic ndex); 
apo A-1 and B concentrations; and apo B/apo A-1 ratio were compared between 
these 2 HDL-C subgroups. 
Tolerability Assessment 
The clinical tolerability of simvastatin was assessed using vital sign measure- 
ments and laboratory analyses, including liver function tests (serum concentra- 
tions of aspartate aminotransferase [AST], alanine aminotransferase [ALT], cre- 
atine kinase [CK], and creatinine [SCr]). Abnormal concentrations were defined 
as follows: AST or ALT, >3-fold the upper limit of normal (ULN) (normal ranges, 
10-35 and 6-35 IU/L, respectively); SCr, ___1.2; and CK, >3 × ULN (normal range, 
___220 IU/L). Other adverse events obtained by spontaneous reporting by the 
patients or asked about by the investigators were recorded at the week-4 clinic 
visit, and the causal relationship to simvastatin was assessed by the investigators 
as being definite, probable, or possible. 
Treatment compliance was assessed using a pill count at the clinic visit. 
Statistical Analysis 
The comparisons of continuous variables between baseline and study end 
were performed using a 2-tailed, paired t test. The rates of change in serum 
lipid concentrations between the lower and higher baseline HDL-C groups 
were compared using a 2-tailed, unpaired t test. StatView version 4.54 (SAS 
Institute Inc., Cary, North Carolina) was used in the statistical analysis. Differ- 
ences were considered statistically significant if Pwas <0.05. Data are expressed 
as mean (SD). 
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RESULTS 
Patient Population 
Twenty-two patients participated in the study (16 women, 6 men; mean [SD] 
age, 56.0 [8.0] years; mean [SD] BMI, 23.6 [3.4] kg/m 2) (Table I). The mean (SD) 
baseline concentrations of serum TC, LDL-C, HDL-C, and TG were 283 (22), 187 
(27), 61 (17), and 177 (76) mg/dL, respectively. The study included 3patients who 
smoked and 7 patients with hypertension, all of whom had good blood pressure 
control (systolic/diastolic blood pressure [SBP/DBP], <140/<90 mm Hg). Five 
patients were receiving treatment with antihypertensive drugs (angiotensin II- 
receptor blockers [3 patients] and calcium-antagonists [2]). None of the patients 
were receiving supplemental vitamins or other medications. Based on the JAS 
guidelines, 183 patients were classified as category A; 18, category B1 or B2; and 1, 
category B3. All of the patients completed the study and were compliant with the 
treatment regimen, and none of them required a change in medications. 
Changes in Serum Lipid Profile 
Changes in serum lipid concentrations after 4 weeks of treatment with 
simvastatin 20 mg/d are shown in Table II. Mean serum concentrations of TC, 
LDL-C, and TG decreased significantly (by 28.6%, 40.4%, and 24.0%, respectively; 
all, P < 0.001 vs baseline) (Figure 1). The mean serum HDL-C concentration i -
Table I. Demographic and baseline clinical characteristics of study patients 
(N = 22).* 
Characteristic Value 
Age, mean (SD), y 56.0 (8.0) 
Sex, no. 
Female 16 
Male 6 
BMI, mean (SD), kg/m 2 23.6 (3.4) 
JAS risk category, t no. 
A 3 
B1/B2 18 
B3 1 
Hypertension, no. 7 
Smoking habit, no. 3 
BMI = body mass index; JAS = Japan Atherosclerosis Society] 8 
*No significant between-group differences were found. 
tpatients assigned to risk categories A, B1, B2, and B3 have 0, 1, 2, and 3 major risk fac- 
tors, respectively (major risk factors include aging [men, _>45 years; women, _>55 years], 
hypertension, diabetes mellitus, smoking habit, family history of coronary heart disease, 
and/or high-density lipoprotein cholesterol evel <40 mg/dL), in addition to an elevated 
low-density lipoprotein cholesterol (LDL-C) concentration (categories A, B1/B2, and B3, 
LDL-C _>160, _>140, and _>120 mg/dL, respectively) without coronary heart disease. 
Patients with diabetes mellitus were classified as category B3 even if their only other 
major risk factor was an elevated LDL-C concentration] 8 
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Table II. Serum lipid concentrations before (week 0; baseline) and after 
4 weeks of treatment with simvastatin 20 mg/d in Japanese pa- 
tients with hyperlipidemia (N -- 22). Values are mean (SD). 
Parameter Week 0 Week 4 
TC, mg/dL 283 (22) 202 (20)* 
LDL-C, mg/dL 187 (27) 112 (23)* 
HDL-C, mg/dL 61 (17) 65 (16)* 
Non-HDL-C, mg/dL 222 (30) 1 37 (24)* 
Non-HDL-C/HDL-C ratio t 4.0 (1.7) 2.3 (0.8)* 
TG, mg/dL 177 (76) 126 (46)* 
TC = total cholesterol; LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density 
lipoprotein cholesterol; TG = triglycerides. 
*P < 0.001 versus baseline (paired t test). 
tAtherogenic index. 
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Figure 1. Percentage changes from baseline in serum lipid concentrations after 
4 weeks of treatment with simvastatin 20 mg/d in Japanese patients with 
hyperlipidemia. TC -- total cholesterol; LDL-C -- low-density lipoprotein cho- 
lesterol; HDL-C -- high-density lipoprotein cholesterol; TG -- triglycerides. 
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creased significantly from baseline (by 7.2%; P < 0.001 vs baseline). The mean ser- 
um non-HDL-C concentration and atherogenic ndex (non-HDL-C/HDL-C ratio) 
improved significantly (by 38.3% and 42.1%, respectively; both, P < 0.001 vs 
baseline) (Table II). 
A significant increase in mean apo A-1 concentration (by 6.9%) and significant 
decreases in mean apo B and E concentrations (by 34.0% and 28.5%, respectively) 
were observed (all, P< 0.001 vs baseline) (Table llI). The mean apo B/apo A-1 ratio 
also decreased significantly (by 38.5%; P < 0.001 vs baseline), as did the mean 
serum lipid peroxide concentration (by 14.5%; P < 0.01 vs baseline). 
Achievement of TC and LDL-C Targets 
Table IV shows the percentages of patients who achieved serum TC and LDL-C 
targets, by JAS category. 18Overall, targets were achieved by 20 (90.9%) of 22 pa- 
tients. In the patients in categories B1 and B2, who accounted for 81.8% (18 pa- 
tients) of the study population, 16 (88.9%) achieved goals. 
Table V shows the changes in mean serum lipid and apo concentrations at 
baseline and study end. The lower HDL-C group had a higher mean (SD) base- 
line serum TG concentration compared with that in the higher HDL-C group 
(222 [82] vs 145 [53]; P< 0.05). The percentage changes from baseline in mean 
serum HDL-C (Figure 2A) and TG (Figure 2B) concentrations were signifi- 
cantly greater in the lower baseline HDL-C group compared with those in 
the higher baseline HDL-C group (HDL-C, 11.3% vs 4.4%; TG, 34.7% vs 16.5%; 
both, P < 0.05). However, the percentage changes in mean serum concentra- 
tions of TC, LDL-C, apo A-l, and apo B were not significantly different between 
the 2 subgroups. 
Tolerability 
No serious adverse vents were observed, and none of the patients required 
hospitalization or died during the study. 
Table III. Apolipoprotein (apo) and lipid peroxide concentrations before 
(week 0; baseline) and after 4 weeks of treatment with simva- 
statin 20 mg/d in Japanese patients with hyperlipidemia (N -- 22). 
Values are mean (SD). 
Variable Week 0 Week 4 
Apo A-l, mg/dL 1 61 (46) 1 72 (49)* 
Apo B, mg/dL 140 (18) 92 (17)* 
Apo E, mg/dL 6.1 (2.2) 4.4 (1.4)* 
Apo B/apo A-1 ratio 0.9 (0.3) 0.6 (90.2)* 
Lipid peroxide, nmol/mL 2.9 (0.7) 2.5 (0.5) t 
*P < 0.001 versus baseline (paired t test). 
tp < 0.01 versus baseline (paired t test). 
619 
CURRENT THERAPEUTIC RESEARCH 
°~ 
E 
¢; 
°~ 
¢; 
e- 
e- 
e- 
¢; 
°~ 
¢; 
e-  
e- 
°~ 
07  
E 
0 
¢N 
e- 
°~ 
E 
e-  
¢; 
E 
~ . 
e-  ¢N 
~ H 
~z  
N 
~u'~ 
~d 
_Q r -  
-Uo-e, 
0 • 
O ._O ~c 
~-E 
0 • 
~. . .0  
~-E 
0 
u 
,",,4 " "q  
S '~S"  
0 00 0 
00 
0 0 0 
v v v 
S '~S"  
0 00 0 
Pc7 M~ ~ 
0 0 0 
'~" C",l 0 
P',I P',I P',I 
v v v 
~._c ~ 
~-E .  
0"~0 ~"  
t -  Q . .O  • ~..=_ ~ E 
t-" ~. 0 
t -  
O 
2 -  
t -  
t -  
O~ 
t~ 
Y 
E 
t~ 
t-- 
~ - '~0  ~ 0 
0 ~ ~ r - . - - - -~b  : 0 -~ r-  
~ ._  L ~ U  o 
~ ~,o~ -~ 
¢;"~ ~"~" 0 ~ 
• ~_~ r -V  t -  ¢; 
-b~ ¢ -~ .~- -~ 
~cE>~ c 
..~ ..~ ~ 0 ~ ~; 
~.-~--  AI ~ ~. 4-.~ 
620 
H. Yoshida et aL 
Table V. Lipid and apolipoprotein (apo) concentrations before (week O; baseline) and 
after 4 weeks of treatment with simvastatin 20 mg/d in Japanese patients 
with hyperlipidemia, by baseline high-density lipoprotein cholesterol (HDL-C) 
concentration. Values are mean (SD). 
HDL-C <50 mg/dL HDL-C ->50 mg/dL 
(n=9) (n=13) 
Parameter Week 0 Week 4 Week 0 Week 4 
TC, mg/dL 285 (27) 198 (24)* 281 (19) 204 (17)* 
LDL-C, mg/dL 196 (32) 121 (26)* 179 (21) 104 (18)* 
HDL-C, mg/dL 44 (5) 49 (5)* 73 (10) 76 (10) t 
Non-HDL-C, mg/dL 241 (29) 150 (26)* 208 (22) 128 (18)* 
Non-HDL-C/HDL-C ratio 5.6 (1.4) 3.1 (0.7)* 2.9 (0.7) 1.7 (0.4)* 
TG, mg/dL 222 (82) 142 (52)~ 145 (53) 116 (40) t 
Apo A1, mg/dL 1 22 (16) 132 (1 3) t 188 (40) 200 (45)~ 
Apo B, mg/dL 149 (16) 100 (18)* 1 34 (17) 87 (15)* 
Apo B/apo A1 ratio 1.3 (0.3) 0.8 (0.2)* 0.7 (0.1) 0.5 (0.1)* 
TC = total cholesterol; LDL-C = low-density lipoprotein cholesterol; TG = triglycerides. 
*P < 0.001 versus baseline (paired t test). 
tp < 0.05 versus baseline (paired t test). 
~P < 0.01 versus baseline (paired t test). 
No clinically significant concentrations of serum hepatic enzymes were 
found (Table VI). SCr concentrations were below the ULN in all patients. Serum 
CK concentration was <220 IU/L in all patients, and none exhibited clinically 
significant levels. 
DISCUSSION 
Statins have been the most potent agents used for reducing serum LDL-C con- 
centration since they became commercially available -20 years ago. The effects 
of statins as primary and secondary prevention of CHD have been estab- 
lished. 2-13,18 The major independent CHD risk factors originally identified in the 
Framingham Heart Study (10-year isk assessment for CHD) 23 include elevated 
serum concentrations of TC and LDL-C, a depressed serum HDL-C concentra- 
tion, hypertension (SBP/DBP ___140/___90 mm Hg), smoking habit, and older age 
(---65 years). 24-26 Guidelines for the management of individual CHD risk factors 
have been published by the National High Blood Pressure Education Program, 27 
the American Diabetes Association, 28and the National Cholesterol Education 
Program Third Adult Treatment Panel (ATP III). 15 In the ATP III guideline, 15 
reducing the severity of the metabolic syndrome was considered a secondary 
goal in CHD risk reduction, following the primary goal of decreasing the serum 
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Table Vl. Serum concentrations before (week 0; baseline) and after 4 weeks of treat- 
ment with simvastatin 20 mg/d in Japanese patients with hyperlipidemia 
(N -- 22). Values are mean (SD). 
Parameter NV Week 0 Week 4 P 
AST, IU/L 10-35 23.6 (7.4) 24.3 (7.5) 0.483 
ALT, IU/L 6-35 27.0 (22.8) 28.3 (22.3) 0.256 
CK, IU/L <200 112 (45) 119 (51) 0.104 
SCr, mg/dL <1.2 0.64 (0.21) 0.65 (0.19) 0.718 
NV = normal value; AST = aspartate aminotransferase; ALT = alanine aminotransferase; CK = creatine 
kinase; SCr = serum creatinine. 
LDL-C concentration. These goals are in contrast o the Framingham CHD risk 
reduction, determined using age, sex, TC, HDL-C, smoking status, and SBP. 5'25'26 
Before the statins became available, the LDL-C target was not achieved in 
the majority of patients who received lipid-lowering treatment. 19,29 The Lipid 
Treatment Assessment Project, 29 a multicenter survey for a community-based 
assessment of lipid-lowering pharmacotherapy conducted in clinical practice 
settings in the United States and based on the ATP II guideline, 3° found a high 
frequency (82%) of prescribing of lipid-lowering agents. LDL-C goals were 
achieved in 38.4% of 5601 patients overall, 68% of whom were low risk (LDL-C 
goal, <160 mg/dL); 37% of whom were high risk (LDL-C goal, <130 mg/dL); and 
18% of whom had clinically evident CHD (LDL-C goal, <100 mg/dL). 
In Japan, the prescription of simvastatin at a dose of >10 mg/d to hyperlip- 
idemic patients was not approved until 2002. A reduction of 28.9% in serum 
LDL-C concentration was observed with simvastatin 5 mg/d in the Japan Lipid 
Intervention Trial (J-LIT), 31 which studied primary CHD prevention with simva- 
statin use and in which 90.7% of 47,294 patients had completed 6 years of treat- 
ment. Reductions in serum concentrations of LDL-C and apo B of 27.6% and 
21.8%, respectively, were observed in a separate 4-week clinical study of sim- 
vastatin 5 mg/d in 24 Japanese patients with hyperlipidemia conducted by the 
present authors. 2° In the current study, greater eductions in serum LDL-C and 
apo B concentrations (40.4% and 34.0%, respectively) were achieved with sim- 
vastatin 20 mg/d compared with those found in our previous tudy. 2° The reduc- 
tion of -40% in serum LDL-C concentration seems comparable to that achieved 
with simvastatin 40 mg/d or atorvastatin 10 to 20 mg/d in patients with hyper- 
lipidemia in Western countries 19,32 and by rosuvastatin 2.5 mg/d in Japanese 
patients with hyperlipidemia. 33 Stein et a134 reported that simvastatin 20 mg/d 
was associated with a 29% reduction in serum LDL-C concentration i  22 US pa- 
tients with hyperlipidemia,  reduction was similar to that achieved with sim- 
vastatin 5 mg/d in Japanese patients with hyperlipidemia. 2°,31 The results of the 
current study are consistent with those of the landmark studies of atorvastatin 
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10 mg/d and simvastatin 40 mg/d conducted in Western countries, in which sig- 
nificant reductions in CHD risk and LDL-C concentrations were achieved in pa- 
tients with hyperlipidemia. 8,11-13 
These studies 8,11 might predict he reduction in CHD risk achieved with sim- 
vastatin 20 mg/d in Japanese hyperlipidemic patients. However, the ability of 
simvastatin to reduce CHD morbidity and mortality in Japanese patients needs 
to be studied further because the present study investigated only lipid profile 
changes, a surrogate marker for reduced CHD risk. In the current study, 88.9% of 
patients in risk categories B1 and B2 achieved JAS 18 LDL-C targets with simva- 
statin 20 mg/d use, whereas in a meta-analysis of Western comparative trials, 19 
81% of 249 patients in categories B1 and B2 achieved JAS 18 LDL-C targets with the 
use of simvastatin 20 mg/d. The present small-scale pilot study suggests that the 
lipid profiles of Japanese hyperlipidemic patients might be more responsive to 
treatment compared with those in hyperlipidemic patients in Western countries: 
90.9% of the study patients achieved the JAS 18 TC and LDL-C goals. All of the 
patients reported compliance with the 4-week regimen of simvastatin 20 mg/d, 
which might explain the greater esponse to cholesterol-lowering treatment in 
this study compared with that in previous tudies of simvastatin. 2°'31 
In the 2 previous tudies of simvastatin i Japanese patients, 2°,31 the increase 
in serum HDL-C concentration with the use of simvastatin 20 mg/d was nearly 
2-fold that with the use of a 5-mg/d dose. A low serum HDL-C concentration is 
considered a primary CHD risk factor, as indicated in the Framingham Heart 
Study. 23,35,36 In several studies, 37-39 including the Prospective Cardiovascular Mun- 
ster (PROCAM) study, 38 a serum HDL-C concentration <39 mg/dL was found to 
be a significant risk factor for myocardial infarction regardless of LDL-C cate- 
gory. The PROCAM study also found that a high serum HDL-C concentration 
(___48 mg/dL) was more protective than a low serum LDL-C concentration 
(___132 mg/dL). Namely, this protective ffect against myocardial infarction re- 
mained after adjustment ofother risk factors, including elevated LDL-C and TG con- 
centrations. In J-LIT, 31 patients with HDL-C >50 mg/dL had a lower CHD risk (as 
measured by elevated HDL-C) compared with those with HDL-C ---50 mg/dL. 
Similarly, in the present study, simvastatin 20 mg/d was associated with a sig- 
nificantly greater increase in serum HDL-C concentration i  the subgroup with 
the lower baseline HDL-C level compared with that in the subgroup with the 
higher baseline HDL-C level. In contrast, in a US study comparing the efficacy 
and tolerability of simvastatin 80 mg/d versus atorvastatin 80 mg/d adminis- 
tered for 24 weeks, 4° 6 to 12 weeks of treatment with simvastatin 80 mg/d was 
associated with statistically similar HDL-C increases between the lower (11.6%) 
and higher (6.9%) baseline HDL-C subgroups. 4°As great an increase in HDL-C 
might be achieved with the use of simvastatin 20 mg/d in Japanese patients as 
was seen with simvastatin 80 mg/d in patients in the US study, 4° thereby result- 
ing in a decreased CHD risk in patients with low baseline serum HDL-C concen- 
trations. Our findings suggest hat the HDL-C increase and LDL-C decrease 
might be greater in Japanese dyslipidemic patients compared with those in dys- 
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lipidemic patients in Western countries. However, comparative clinical trials 
are needed to support hese findings. 
HDL-C and apo A-1 concentrations increased significantly with simvastatin 
20 mg/d in this study. In contrast, apo A-1 did not change significantly with the 
use of simvastatin 5 mg/d in our previous tudy. 2° Apo A-l, a major apolipopro- 
tein of HDL-C, helps protect hyperlipidemic patients against CHD. 4,5 Although a 
reduced concentration of apo B is effective in preventing atherosclerosis, the 
increased apo A-1 concentration achieved with simvastatin therapy is prefer- 
able in hyperlipidemic patients because apo A-1 reduces the risk for atheroscle- 
rosis through reverse cholesterol transport mechanisms and inhibition of 
lipoprotein oxidation. 4,5 The statin-induced increase in apo A-1 concentration 
has been attributed to the increase in apo A-1 mRNA production resulting from 
the activation of peroxisome proliferator-activated r ceptor ¢z (PPAR-¢0. 41 This 
PPAR-cz-dependent i crease in apo A-1 might occur with simvastatin 20 mg/d 
but not with 5 mg/d, which might in turn lead to the increased HDL-C found with 
the use of simvastatin 20 mg. 
A significant decrease in serum TG concentration was also found with the 
use of simvastatin 20 mg. However, in J-LIT, 31 no significant changes in TG con- 
centration were observed. In the present study, the subgroup with lower base- 
line HDL-C had a higher baseline TG concentration compared with that in the 
subgroup with higher baseline HDL-C, suggesting that fasting serum TG con- 
centration might be inversely correlated with baseline HDL-C concentra- 
tion. 35'36'42'43 The decrease in serum TG concentration was significantly greater 
in the subgroup with the lower baseline HDL-C compared with that in the 
subgroup with higher baseline HDL-C. The impairment of TG-rich lipoprotein 
catabolism resulting from reduced activity of lipoprotein lipase can create 
atherogenic lipoprotein characteristics (ie, depressed HDL-C concentration a d 
elevated small, dense [SD] LDL concentration). These abnormalities in lipid 
profile occur frequently in patients with the metabolic syndrome and/or dia- 
betes and might lead to increased CHD risk. 43~16 Although the mechanisms of 
statin-induced amelioration of these atherogenic characteristics have not been 
fully elucidated, the use of simvastatin 20 mg/d is likely to be associated with 
an improved lipid profile beyond a decreased LDL-C concentration. 
In our previous tudy of simvastatin 5 mg, 2° the oxidative susceptibility of 
LDL (as measured using lag time before propagation of lipid peroxidation) was 
not reduced, and serum concentrations of TG and HDL-C did not change signif- 
icantly from baseline. 2° In the present study, serum lipid peroxide and TG levels 
decreased and HDL-C increased significantly with the use of simvastatin 20 mg. 
The reduction in lipid peroxide level might be related to the changes in TG and 
HDL-C concentrations: increased HDL-C concentration has been found to en- 
hance protection against LDL oxidation, and reduced TG concentration has 
been found to decrease SD-LDL, which is susceptible to oxidation. 47~9 However, 
further studies are needed to determine whether all statins have a beneficial 
effect on the oxidative susceptibility of LDL. 5° 
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This s tudy had several  l imitations. First, there was no control group with 
which to compare  the s imvastat in group. A randomized, double-arm study in 
which the results from a placebo group or a s imvastat in 5-mg/d group could be 
compared with those from a group receiving simvastat in 20 mg/d is needed. 
Second, the duration of t reatment  was relatively short  (4 weeks), and the short-  
term effects found in this s tudy might differ from the long-term effects. Third, 
the study populat ion was small (22 patients); large-scale, comparat ive  studies 
are needed. 
CONCLUSIONS 
The results of this s tudy suggest hat s imvastat in 20 mg/d might be useful in the 
clinical t reatment  of hyperl ip idemia in Japanese patients in the initial dose set- 
ting. JAS TC and LDL-C targets were achieved in 90.9% of all part icipants. The 
study drug was well tolerated. 
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